Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Molecular Driven Phase II Trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib, Selected According to HRD Status, in Patients With Advanced (Stage III B-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer Preceded by a Phase I Dose Escalation Study on Rucaparib-Bevacizumab Combination
Brief Summary: This trial is a randomized, open-label Phase I-2 multi-center study designed to evaluate the effect of Carboplatin-Paclitaxel-Bevacizumab (in combination and maintenance) vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib (Rucaparib only in maintenance) vs Carboplatin-Paclitaxel-Rucaparib (Rucaparib only in maintenance) on progression-free survival in patients with advanced high grade ovarian cancer treated according to HRD status . The trial will test the hypothesis that Carboplatin-Paclitaxel-Bevacizumab-Rucaparib and the Carboplatin-Paclitaxel-Rucaparib arms will improve the progression-free survival in comparison to standard Carboplatin-Paclitaxel-Bevacizumab in HRD negative (HR proficient) patients and that Carboplatin-Paclitaxel-Bevacizumab-Rucaparib will improve PFS with respect to Carboplatin-Paclitaxel-Rucaparib in HRD positive patients. The randomized phase of the study will be preceded by a single arm Phase I study which will be conducted only in the National Cancer Institute of Milan, aiming at evaluating the MTD of the combination Rucaparib-Bevacizumab. Once the MTD has been reached, the randomized study will start.


Options:
A: Arm Label: Standard treatment; Type: OTHER; Interventions: Drug: Carboplatin, Drug: Paclitaxel, Drug: Bevacizumab | Arm Label: Carboplatin + Paclitaxel + Bevacizumab + Rucaparib; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Paclitaxel, Drug: Bevacizumab, Drug: Rucaparib | Arm Label: Carboplatin + Paclitaxel + Rucaparib; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Paclitaxel, Drug: Rucaparib | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Carboplatin + Paclitaxel + Bevacizumab + Rucaparib, Carboplatin + Paclitaxel + Rucaparib, Standard treatment | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Carboplatin + Paclitaxel + Bevacizumab + Rucaparib, Carboplatin + Paclitaxel + Rucaparib, Standard treatment | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Carboplatin + Paclitaxel + Bevacizumab + Rucaparib, Standard treatment | Intervention Type: DRUG; Name: Rucaparib; Assigned to Arm(s): Carboplatin + Paclitaxel + Bevacizumab + Rucaparib, Carboplatin + Paclitaxel + Rucaparib
B: Arm Label: Pembrolizumab + paclitaxel ± bevacizumab; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab, Drug: Paclitaxel, Drug: Bevacizumab, Drug: Docetaxel | Arm Label: Placebo + paclitaxel ± bevacizumab; Type: PLACEBO_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Bevacizumab, Other: Placebo for pembrolizumab, Drug: Docetaxel | Intervention Type: BIOLOGICAL; Name: Pembrolizumab; Assigned to Arm(s): Pembrolizumab + paclitaxel ± bevacizumab | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Pembrolizumab + paclitaxel ± bevacizumab, Placebo + paclitaxel ± bevacizumab | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Pembrolizumab + paclitaxel ± bevacizumab, Placebo + paclitaxel ± bevacizumab | Intervention Type: OTHER; Name: Placebo for pembrolizumab; Assigned to Arm(s): Placebo + paclitaxel ± bevacizumab | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Pembrolizumab + paclitaxel ± bevacizumab, Placebo + paclitaxel ± bevacizumab
C: Arm Label: DOXIL + trabectedin; Type: EXPERIMENTAL; Interventions: Drug: Trabectedin, Drug: DOXIL, Drug: Dexamethasone | Arm Label: DOXIL; Type: ACTIVE_COMPARATOR; Interventions: Drug: DOXIL | Intervention Type: DRUG; Name: Trabectedin; Assigned to Arm(s): DOXIL + trabectedin | Intervention Type: DRUG; Name: DOXIL; Assigned to Arm(s): DOXIL, DOXIL + trabectedin | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): DOXIL + trabectedin
D: Arm Label: AMG 386; Type: EXPERIMENTAL; Interventions: Drug: AMG 386, Drug: Paclitaxel | Arm Label: AMG 386 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: AMG 386 Placebo, Drug: Paclitaxel | Intervention Type: DRUG; Name: AMG 386; Assigned to Arm(s): AMG 386 | Intervention Type: DRUG; Name: AMG 386 Placebo; Assigned to Arm(s): AMG 386 Placebo | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): AMG 386 | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): AMG 386 Placebo

Answer: A